Abstracts tagged "Lung Disease"

Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…
Abstract Number: 274 • 2015 ACR/ARHP Annual Meeting
Shrinking Lung Syndrome in Connective Tissue Disease
Helena Borrell Paños¹, Javier Narváez², Juan José Alegre³, Ivan Castellvi⁴, Francesca Mitjavila⁵, Eulalia Armengol¹, Joan Miquel Nolla¹ and Maria Molina⁶, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Shrinking lung syndrome (SLS) is a rare a little known complication associated with systemic lupus erythematosus (SLE) and other connective tissue diseases (CTDs). This…
Abstract Number: 304 • 2015 ACR/ARHP Annual Meeting
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
Michael George¹, Maryl Kreider², Rupal Shah², Wallace Miller Jr.³, Peter A. Merkel⁴ and Victoria Werth^5,6, ¹Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ⁶Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is common in classic dermatomyositis (DM) and clinically amyopathic dermatomyositis (CADM), in which rash is present without weakness. Previous studies…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
Abstract Number: 1574 • 2015 ACR/ARHP Annual Meeting
Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell Klassen⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Daniel Anderson⁷, Harlan Sayles⁷, Kaleb Michaud⁸, Liron Caplan⁹, Lisa A. Davis⁹, Grant W. Cannon¹⁰, Brian Sauer¹¹, E. Blair Solow¹², Andreas Reimold¹³, Gail S. Kerr¹⁴, Pascale Schwab¹⁵, Joshua F. Baker¹⁶ and Ted R. Mikuls¹⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Research Services 151, Omaha VA Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁹Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴VAMC, Georgetown University, Washington, DC, ¹⁵Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Mortality from cardiovascular (CV) and respiratory causes is increased in rheumatoid arthritis (RA). Predictive serologic biomarkers of these events are lacking. Previously, we have…
Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
Abstract Number: 1612 • 2015 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases
Seung-Cheol Shim¹, In-Seol Yoo², Su-Jin Yoo¹, Young Kim¹, Jinhyun Kim³ and Seong-Wook Kang², ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose: Lung diseases (LD) are common extra-articular manifestations in rheumatoid arthritis (RA). Recent studies have shown the association of RA-LD with anti-citrullinated protein antibodies. The…
Abstract Number: 1881 • 2015 ACR/ARHP Annual Meeting
Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?
Javier Narváez¹, Sergi Heredia², Helena Borrell Paños², Eulalia Armengol², Eugenia De Lama³ and Jose Antonio Narvaez³, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Radiology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Several studies have shown that gastroesophageal reflux disease (GERD) is a risk factor in the progression of idiopathic pulmonary fibrosis. In systemic sclerosis (SSc),…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 1902 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group
Lama Sakr¹, Elie Younanian², Marie Hudson³, Mianbo Wang⁴, Murray Baron⁵ and Sasha Bernatsky⁶, ¹Division of Pulmonary Diseases, Jewish General Hospital, Montreal, QC, Canada, ²Division of Pulmonary Diseases, McGill University, Montreal, QC, Canada, ³McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The literature supports an increased incidence of certain malignancies in patients with systemic sclerosis (SSc), including lung cancers. Predictors of lung cancer in SSc…
Abstract Number: 2600 • 2015 ACR/ARHP Annual Meeting
Signs of Immune Activation and Local Inflammation Are Present in the Bronchial Tissue of Patients with Untreated Early Rheumatoid Arthritis
Gudrun Reynisdottir^1,2, Helga Olsen³, Vijay Joshua⁴, Marianne Engström², Magnus Skold³, Anders Eklund⁵, Johan Grunewald³ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ³Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Events in the lungs might contribute to generation of anti citrullinated protein antibodies (ACPA) in rheumatoid arthritis (RA). We investigated if signs of immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].